ThermoGenesis reveals intellectual property acquisition by ImmuneCyte
By Akshay Kedari  Date: 2020-04-14

ThermoGenesis reveals intellectual property acquisition by ImmuneCyte

ThermoGenesis Holdings, Inc. has recently announced the acquisition of intellectual property by ImmuneCyte Life Sciences, its joint venture. The acquisition has been made by ThermoGenesis, a market leader and pioneer in the development & commercialization of automated cell processing technologies, to develop full human antibody therapeutics for COVID-19 disease.

The intellectual property that has been procured includes 4 monoclonal antibody drug candidates with high affinity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as tools for quantifying and screening efficacy of the neutralizing antibodies. These high-affinity antibodies have been obtained by screening the enriched libraries of B cell from people who have recovered from the COVID-19 disease recently. These technologies were developed by a team of researchers who work under East China Normal University, which is a prestigious university in China. The deal also includes an upfront cash payment for an undisclosed sum as well as low double-digit revenue sharing for the drug candidates.

The recent acquisition is another step towards the development of drug candidates or vaccine for emergency treatment of the patients infected by coronavirus. The convalescent plasma therapy has been applied for this treatment by giving current patients an infusion of plasma from individuals recovered from the disease. ThermoGenesis is developing this therapy by using its IgG/IgM Antibody Fast Detection Kit for SARS-CoV-2. Through the combination of this detection kit with the newly acquired technology by ImmuneCyte, the company will detect individuals who have acquired protective immunity against the coronavirus. Its proprietary cell processing platform will then allow the simultaneous isolation of immune cells and convalescent plasma for the effective development of potential anti-COVID-19 antibody.

The entrance of coronavirus into the cells can be blocked effectively by neutralizing antibodies, which are key effectors in the convalescent plasma, thus achieving anti-viral effects. The recent acquisition can lead to the further development of purified anti-COVID-19 monoclonal and polyclonal neutralizing antibodies as these can be more potent and safer with higher efficacy as compared to convalescent plasma.

Source credit:

https://thermogenesis.com/thermogenesis-announces-its-immunecyte-joint-venture-acquires-key-technologies-to-develop-fully-human-polyclonal-and-monoclonal-antibody-therapeutics-for-covid-19/

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Innovaccer unveils AI-enabled patient relationship management solution
Innovaccer unveils AI-enabled patient relationship management solution
By Akshay Kedari

Innovaccer, Inc., a healthcare company, has recently launched an AI (artificial intelligence) enabled patient relationship management solution. The new solution will streamline communication between the care teams and patients. In addition, the solu...

Geely Tech to rollout a smart battery swapping network across Jinan
Geely Tech to rollout a smart battery swapping network across Jinan
By Akshay Kedari

Geely Technology Group, a Chinese automobile manufacturer, and the Municipal Government of Jinan, China, have reportedly signed an all-round strategic cooperation deal to jointly develop a network of smart battery swapping service stations across Jin...

CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
By Akshay Kedari

Chinese biotechnology company, CStone Pharmaceuticals has recently announced that it has completed the Share Subscription Agreement with Pfizer Inc. for its newly issued shares worth US$200 million. The move furthers the biotech’s multifaceted ...

Researchers bag $6Mn grant to study the link between Parkinson’s & aging
Researchers bag $6Mn grant to study the link between Parkinson’s & aging
By Akshay Kedari

A three-year grant worth $6 million, funded by the Michael J. Fox Foundation, was recently awarded to a collaborative research team from Michigan’s Van Andel Institute (VAI) and the University of Minnesota Medical School. The grant was given th...

EY announces availability of OpsChain Network Procurement solution
EY announces availability of OpsChain Network Procurement solution
By Akshay Kedari

Ernst & Young (EY), a global professional services network, has recently announced the availability of a first-of-its-kind OpsChain Network Procurement solution. The solution has been built on the company’s OpsChain platform. It will enabl...